
Opinion|Videos|January 20, 2025
Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1
Panelists discuss how teplizumab binds to T cells and modifies their function to preserve beta cell function, potentially delaying type 1 diabetes onset in at-risk individuals by an average of 2-3 years.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Aggressive Risk Factor Management Reduced Recurrent AF by Nearly Half After Catheter Ablation
2
TMS 2025: Regina Castaneda, MD, on Tirzepatide, Menopause, and Hormone Therapy
3
Screening for Breast Cancer in Patients With Dense Breast Tissue: A Q&A With Donna Plecha, MD
4
Genitourinary Syndrome of Menopause (GSM): Clinical FAQ for Primary Care
5































































































































































































































































































